` ATX (Amplia Therapeutics Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

ATX
vs
S
S&P/ASX 300

Over the past 12 months, ATX has significantly outperformed S&P/ASX 300, delivering a return of +41% compared to the S&P/ASX 300's +4% growth.

Stocks Performance
ATX vs S&P/ASX 300

Loading
ATX
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ATX vs S&P/ASX 300

Loading
ATX
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
ATX vs S&P/ASX 300

Loading
ATX
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Amplia Therapeutics Ltd vs Peers

S&P/ASX 300
ATX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Amplia Therapeutics Ltd
Glance View

Market Cap
61.6m AUD
Industry
Biotechnology

Amplia Therapeutics Ltd. is a medical biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The Company’s pipeline is developing two orally available small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH).

ATX Intrinsic Value
0.14 AUD
Undervaluation 14%
Intrinsic Value
Price
Back to Top